🇺🇸 FDA
Pipeline program

MT-1186

MT-1186-A04

Phase 3 small_molecule terminated

Quick answer

MT-1186 for ALS is a Phase 3 program (small_molecule) at Tanabe Pharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Tanabe Pharma
Indication
ALS
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials